GPCRs exist in multiple conformations that can engage distinct signalling mechanisms which in turn may lead to diverse behavioural outputs. In rodent models, activation of the δ opioid receptor (δ-receptor) has been shown to elicit antihyperalgesia, antidepressant-like effects and convulsions. We recently showed that these δ-receptor-mediated behaviours are differentially regulated by the GTPase-activating protein regulator of G protein signalling 4 (RGS4), which facilitates termination of G protein signalling. To further evaluate the signalling mechanisms underlying δ-receptor-mediated antihyperalgesia, antidepressant-like effects and convulsions, we observed how changes in Gα o or arrestin proteins in vivo affected behaviours elicited by the δ-receptor agonist SNC80 in mice.
Introduction
GPCRs are a diverse family of membrane bound receptors that regulate a wide array of biological functions. Canonically, GPCRs regulate these processes through activation of G proteins which subsequently interact with a variety of downstream effectors. Following agonist activation, a GPCR is phosphorylated by GPCR kinases and internalized following recruitment of arrestins. In recent years, it has become apparent that GPCRs can signal through G proteinindependent mechanisms (Galandrin et al., 2007) by directly recruiting arrestins that can also promote signalling from GPCRs (Reiter et al., 2012) . Furthermore, ligands that act at the same orthosteric site on a receptor can stabilize distinct active conformations that preferentially signal through distinct G protein or arrestin subtypes. This phenomenon, known as functional selectivity or biased agonism, has been observed with many GPCRs including the β 2 adrenoceptor (Drake et al., 2008) , the CB 1 cannabinoid receptor (Hudson et al., 2010) , as well as μ-, κ-and δ-opioid receptors (Pradhan et al., 2012) . The δ opioid receptor (δ-receptor) is a class A GPCR and interacts with Gα i/o proteins. Activation of the δ-receptor in rodents has been shown to produce antinociception, antihyperalgesia, anxiolytic effects and antidepressant-like effects without the constipation, respiratory depression and abuse liability observed with μ-receptor agonists (see Chu Sin Chung and Kieffer, 2013) . In addition, some δ-receptor agonists cause convulsions, which has limited their clinical utility (Comer et al., 1993; Hong et al., 1998) .
The signalling pathways that bring about δ-receptormediated behaviours are only beginning to be understood. Targeted knockdown of specific G protein subunits using antisense nucleotides inhibited δ-receptor-mediated spinal and supraspinal antinociception in mice, implicating multiple Gα i/o subtypes in the regulation of these effects (Standifer et al., 1996; Sánchez-Blázquez and Gárzon, 1998) . Loss of regulator of G protein signalling 4 (RGS4) potentiated the antinociceptive, antihyperalgesic and antidepressant-like effects of the δ-receptor agonist SNC80 suggesting that these behaviours are generated through G protein signalling (Dripps et al., 2017) . However, this study also found that the frequency of SNC80-induced convulsions was not altered in RGS4 knockout mice suggesting that δ-receptor-mediated convulsions may signal through a G protein-independent mechanism. Loss of arrestin 2 (β-arrestin 1) increased the potency of SNC80 to induce mechanical antihyperalgesia, whereas loss of arrestin 3 (β-arrestin 2) produced acute tolerance to the antihyperalgesic effects of the δ-receptor agonists ARM390 and JNJ20788560 (Pradhan et al., 2016) .
Use of a δ-receptor agonist that is biased towards producing the analgesic and antidepressant-like effects could be an effective strategy for improving the safety and clinical utility of δ-receptor ligands. A detailed understanding of the intracellular signalling pathways that give rise to δ-receptormediated behaviours, and δ-receptor-mediated convulsions in particular, is critical for the development of such drugs. Therefore, to gain a better understanding of the downstream signalling mechanisms that give rise to δ-receptor-mediated behaviours, we evaluated how altering Gα o and arrestin molecules affected these behaviours. Specifically, we examined the potency of SNC80 to produce antihyperalgesia, antidepressant-like effects and convulsions in Gα o heterozygous knockout mice, Gα o RGS-insensitive heterozygous knock-in mice and arrestin 2 and arrestin 3 knockout mice.
Methods

Animals
All animal care and experimental procedures complied with the US National Research Council's Guide for the Care and Use of Laboratory Animals (Council, 2011) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Mice were group-housed with a maximum of five animals per cage in clear polypropylene cages with corn cob bedding and nestlets as enrichment. Mice had free access to food and water at all times. Animals were housed in pathogen-free rooms maintained between 68 and 79°F and humidity between 30 and 70% humidity with a 12 h light/dark cycle with lights on at 07:00 h.
The arrestin 3 knockout mouse strain (Arrb2 tm1Rjl/J ) was (Duan et al., 2007) . Mice were backcrossed at least 10 generations into a C57BL/6 background and maintained in-house as heterozygote harem (one male, two females) breeding groups except for arrestin 2 knockout mice which were maintained as homozygote harem breeding groups. C57BL/6 mice are the background strain for all the genetic knockout strains used in this study. C57BL/6 mice were used for all studies as this species is commonly used in pharmacological and behavioural research and is consistent with our previous studies (Dripps et al., 2017) . Wild-type littermates (+/+) were used as controls for all strains except arrestin 2 knockout mice in which case arrestin 3 wild-type littermates were used. For studies in which transgenic mice were not required, C57BL/6 N mice (17-30 g) were obtained from Envigo (formerly Harlan, Indianapolis, IN, USA). The diet of breeder mice in the Gα o RGS-insensitive knock-in, Gα o knockout and arrestin 3 knockout mouse colonies was supplemented with γ-irradiated peanuts in the shell (S6711, Bio-Serv, Flemington, NJ, USA) to enhance litter size and production of transgenic mice. Experiments were conducted in the housing room during the light cycle. All mice were used between 8 and 15 weeks of age at time of experiment and weighed 16-32 g. Mice were tested only once, and all analyses are between-subject with the exception of the hot plate test (within-subject analysis). For in vivo experiments, six mice per experimental condition (e.g. per drug and per genotype) were used with a total of 904 mice used for the entire study.
Forced swim test
The forced swim test (FST) is an assay that is widely used to evaluate the antidepressant-like effects of drugs in rodents (Barkus, 2013) . Our experiments were adapted from Porsolt et al. (1977) and performed as previously described (Dripps et al., 2017) . Briefly, 60 min after SNC80 (0.1, 0.32, 1, 3.2, 10 or 32 mg·kg À1 ) or vehicle injection, each mouse was placed in a 4 L beaker filled with 15 cm of 25 ± 1°C water, and its behaviour was recorded for 6 min using a Sony HDR-CX220 digital camcorder. Videos were analysed by individuals blind to the experimental conditions, and the amount of time the animals spent immobile was quantified. Immobility was defined as the mouse not actively traveling through the water and making only movements necessary to stay afloat. The time the mouse spends immobile after the first 30 s of the assay was recorded.
Nitroglycerin-induced hyperalgesia
The NTG-induced hyperalgesia assay was adapted from Bates et al. (2010) using modifications described in Pradhan et al. (2014) and performed as previously described (Dripps et al., 2017) . In brief, male and female mice were used to evaluate NTG-induced hyperalgesia. Hyperalgesia was assessed by immersing the tail (~5 cm from the tip) in a 46°C water bath and determining the latency for the animal to withdraw its tail with a cut-off time of 60 s. After determining baseline withdrawal latencies, 10 mg·kg À1 NTG (i.p.) was administered to each animal. Tail withdrawal latency was assessed again 1 h after NTG administration. At 90 min post-NTG, animals received an injection of SNC80 (0.32, 1, 3.2, 10 or 32 mg·kg À1 ) or vehicle, and mice were observed continuously in individual cages for 30 min to observe for convulsions (see section below). Tail withdrawal latencies were assessed again 30 min after SNC80 administration.
SNC80-induced convulsions
Mice were observed continuously in individual cages for convulsions. Unless otherwise noted, NTG treatment had no significant effect on the frequency or nature of SNC80-induced convulsions (see Supporting Information). Convulsions were typically composed of a single tonic phase characterized by sudden tensing of the musculature and extension of the forepaws followed by clonic contractions that extended the length of the body. Mice would frequently lose balance and fall on their side, although the so-called barrel rolling was rarely observed. Convulsions were followed by a period of catalepsy that lasted 2-5 min after which the animals were hyperlocomotive but otherwise indistinguishable from untreated controls. The severity of each convulsion was quantified using the following modified Racine (1972) scale adapted from Jutkiewicz et al. (2006) : 1 -teeth chattering or face twitching; 2 -head bobbing or twitching; 3 -tonic extension or clonic convulsion lasting less than 3 s; 4 -tonic extension or clonic convulsion lasting longer than 3 s; and 5 -tonic extension or clonic convulsion lasting more than 3 s with loss of balance. Post-convulsion catalepsy-like behaviour was assessed by placing a horizontal rod under the forepaws of the mouse, and a positive catalepsy score was assigned if the mouse did not remove its forepaws after 30 s. Two arrestin 2 knockout mice that received 32 mg·kg À1 SNC80 exhibited sustained convulsions after the observation period and were killed by pentobarbital overdose.
Hot plate test
The hot plate test was adapted from Lamberts et al. (2011) and was chosen because it has previously been used to evaluate the antinociceptive effects of opioids in arrestin 3 knockout mice (Bohn et al., 1999) . Briefly, mice were placed on a 52°C hot plate, and the latency to lick forepaw(s) or jump was measured with a cut-off time of 60 s in order to prevent tissue damage. To determine baseline latency, mice were placed on the hot plate 30 min after each of two injections of saline.
Following an injection of 32 mg·kg À1 morphine, latency was assessed every 30 min.
δ-receptor saturation binding
Mice were decapitated following cervical dislocation, the forebrain was removed immediately, and membranes were freshly prepared as previously described (Broom et al., 2002a) . Tissue collection without anaesthesia was used to limit modification to δ-receptor number, conformation and/or localization and is conditionally acceptable with justification under the American Veterinary Medical Association Guidelines for the Euthanasia of Animals. Protein concentrations were determined with a BCA assay kit (Thermo Scientific, Rockford, IL, USA). Specific binding of the δ-receptor agonist [ 3 H]DPDPE was determined as described using 10 μM of the opioid antagonist naloxone to define nonspecific binding as described by Broom et al., (2002a) . Reactions were incubated for 60 min at 26°C and stopped by rapid filtration through GF/C filter mats soaked in 0.1% PEI using an MLR-24 harvester (Brandel, Gaithersburg, MD, USA). Bound [ 3 H]DPDPE was determined by scintillation counting, and B max and K d values were calculated using nonlinear regression analysis with GraphPad Prism version 6.02 (GraphPad, San Diego, CA, USA). To ensure the reliability of single values, membranes from each mouse (n = 5 per group) were assayed in triplicate.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All experiments were randomized. Six mice per experimental condition were used, from different home cages and were evaluated across at least 3 different days (or experiments or test days). For in vivo studies, power analysis (α = 0.05; 1-® = 0.9) revealed that for a calculated effect size of 1-3 (Cohen's d), depending on the experiment, a sample size of four to six mice per experimental condition would be needed (G*Power 3.1.9.2; Faul et al., 2007) . All data analysis was performed using GraphPad Prism version 6.02 (GraphPad, San Diego, CA, USA). For all tests, level of significance (α) was set to 0.05. Post hoc analysis was conducted using the Sidak's post hoc test to correct for multiple comparisons. Post hoc analysis was only performed when F values achieved P < 0.05. All values in the text are reported as mean ± SEM. ED 50 values were calculated using GraphPad Prism version 6.02 by extrapolating the 50% maximum effect from the straight line analysis of the averaged treatment group data used to generate each dose effect function.
Materials
All drugs were injected at a volume of 10 mL·kg À1 unless 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
δ-receptor-mediated behaviours in Gα o RGS-insensitive mice
It has previously been demonstrated that loss of RGS4 potentiates δ-receptor-mediated antihyperalgesia and antidepressantlike effects but not δ-receptor-mediated convulsions (Dripps et al., 2017) . To further investigate the signalling mechanisms involved in these behaviours, we characterized these behaviours in Gα o RGS-insensitive heterozygous mice. The Gα o RGSinsensitive heterozygous mice have one copy of GNAO1 with a G184S point mutation that prevents binding of all RGS proteins to Gα o and should enhance signalling from those G proteins (Goldstein et al., 2009; Lamberts et al., 2013) . First, the potency of SNC80 to reverse NTG-evoked thermal hyperalgesia was evaluated in Gα o RGS-insensitive heterozygous mice (+/GS) and their wild-type littermates (+/+; Figure 1A ). The +/GS mice did not differ significantly from wild-type littermates in their baseline tail withdrawal latencies prior to NTG treatment (+/+: 42.4 ± 2.5 s, +/GS: 41.4 ± 1.4 s). Administration of 10 mg·kg À1 NTG significantly decreased tail withdrawal latency to a similar degree in both genotypes (+/+: 6.1 ± 1.3 s, +/GS: 5.4 ± 0.3 s). Two-way ANOVA revealed a significant interaction [SNC80 dose X genotype, F(5,60) = 7.61], as well as significant main effects of SNC80 dose [F(5,60) ) and a significant increase in the maximum effect observed in the +/GS mice compared with their wild-type littermates. Overall, the potency and efficacy of SNC80 to increase tail withdrawal latency was enhanced in Gα o RGSinsensitive heterozygous mice.
The potency of SNC80-induced antidepressant-like effects in Gα o RGS-insensitive heterozygous mice was evaluated in the FST ( Figure 1B ). In the absence of drug treatment, +/GS mice had lower immobility scores than wild-type littermates. SNC80 significantly decreased immobility scores to a greater extent in +/GS mice compared to wild-type littermates. Due to the basal differences in immobility scores, scores were normalized to a percentage relative to vehicletreated mice of the appropriate genotype ( Figure 1C) . Twoway ANOVA of the transformed data revealed significant main effects of SNC80 dose [(vehicle and 0.32-10 mg·kg To investigate whether Gα o RGS-insensitive heterozygous mice were hyper-responsive to a wider array of antidepressive drugs, the effects of the tricyclic antidepressant desipramine were evaluated in the FST ( Figure 1D ). Desipramine produced decreases in immobility [main effect of desipramine dose: F(2,30) = 12.43], but there was no effect of genotype and no significant interaction.
Although loss of RGS4 did not alter SNC80-induced convulsions, other RGS proteins may play a role in regulating this behaviour. Therefore, we evaluated SNC80-induced convulsions in Gα o RGS-insensitive heterozygous mice and wild-type littermates and scored convulsion severity using a modified Racine scale ( Figure 1E ). SNC80 produced similar dose-dependent increases in convulsion severity in both genotypes. There were no significant differences in the frequency of convulsions or time of onset and duration of SNC80-induced convulsions (see Supporting Information).
It is possible that the enhanced behavioural effects of SNC80 in Gα o RGS-insensitive heterozygous mice are due to a change in receptor density or agonist affinity for the δ-receptor relative to their wild-type littermates. To evaluate potential changes in these parameters, saturation binding with the radiolabeled δ-receptor agonist [ 3 H]DPDPE was performed using brain tissue from Gα o RGS-insensitive +/+ and +/GS mice. There were no significant differences in total receptor number of the +/GS mice compared to wild-type littermates (Table 1 ; Figure 1F ). In addition, there were no changes in the affinity of [ 3 H]DPDPE for the δ-receptor in the Gα o RGS-insensitive heterozygous mice.
δ-receptor-mediated behaviours in Gα o heterozygous knockout mice
To further evaluate the role of Gα o in δ-receptor-mediated behaviours, we characterized δ-receptor-mediated antihyperalgesia, antidepressant-like effects and convulsions in Gα o heterozygous knockout mice. Gα o null mice rarely survived to weaning (Lamberts et al., 2011) . Therefore, we chose to only evaluate Gα o wild-type and heterozygous knockout mice. Prior to NTG administration, there were no significant differences in tail withdrawal latency in Gα o wild-type and heterozygous knockout mice (+/+: 41.2 ± 1.8 s, +/À: 40.3 ± 2.0 s). Administration of 10 mg·kg À1 NTG produced similar decreases in tail withdrawal latency in both genotypes (+/+: 4.9 ± 0.5 s, +/À: 4.1 ± 0.3 s). In Gα o wild-type mice, SNC80 produced dose-dependent increases in tail withdrawal latency following NTG administration (Figure 2A ). This effect was absent in Gα o heterozygous knockout mice. Two-way In the FST, SNC80 produced significant decreases in immobility in both the Gα o wild-type and heterozygous knockout mice [ Figure 2C ; Two-way ANOVA main effect of SNC80 dose: F(4,50) = 22.05]. However, there were no significant differences between genotypes in the immobility scores produced in response to a given dose of SNC80. SNC80 also produced similar dose-dependent increases in convulsion severity in Gα o wild-type and heterozygous knockout mice ( Figure 2D ). There were no significant differences in frequency of convulsions or the time of onset and duration of SNC80-induced convulsions (see Supporting Information).
The diminished effect of SNC80 on NTG-induced hyperalgesia in Gα o heterozygous knockout mice could be due to decreased receptor density of or agonist affinity at the δ-receptor relative to wild-type littermates. To evaluate potential changes in density or agonist affinity, saturation binding with the radiolabeled δ-receptor Figure 2E ).
δ-receptor-mediated behaviours in arrestin 2 and arrestin 3 knockout mice
To evaluate the potential role of arrestin-mediated mechanisms, we evaluated SNC80-induced antihyperalgesia, antidepressant-like effects and convulsions in arrestin 2 and arrestin 3 knockout mice. There were no significant differences in SNC80-induced antihyperalgesia, antidepressantlike effects or convulsions in the arrestin 3 knockout mice compared to wild-type and heterozygote knockout littermates (Figure 3A -C; Supporting Information). However, the In arrestin 2 knockout mice, SNC80-induced increases in tail withdrawal latency following NTG administration were similar to wild-type controls ( Figure 4A ). Arrestin 2 knockout mice had no significant differences in SNC80-induced decreases in immobility in the FST relative to wild-type mice ( Figure 4B ). In contrast, SNC80-induced convulsions were profoundly altered in arrestin 2 knockout mice such that the potency of SNC80 to induce convulsions was significantly increased in arrestin 2 knockout mice as shown by a leftward shift in the dose-response curve ( Figure 4C These subsequent convulsions were similar in nature to the initial SNC80-induced convulsions, consisting of both tonic and clonic phases followed by a brief (1-2 min) period of catalepsy. In order to reduce the number of animals used, SNC80-induced convulsions were typically evaluated prior to antihyperalgesia measurements (see Methods). However, these mice received NTG prior to SNC80, which may have influenced convulsion frequency. Therefore, SNC80-induced convulsions were also evaluated in drug-naïve mice to confirm the altered convulsive effects of SNC80 in arrestin 2 knockout mice. NTG administration did not alter convulsion severity but produced a non-significant increase in the number of convulsions elicited by 3.2 mg·kg À1 SNC80
( Figure 4C, D) . Despite the significant changes to SNC80-induced convulsions observed in arrestin 2 knockout mice, loss of arrestin 2 did not alter the potency of the chemical convulsant pentylenetetrazol (see Supporting Information).
Discussion
In this report, we sought to further elucidate the downstream signalling molecules that give rise to δ-receptor-mediated behaviours. We found that Gα o and arrestins differentially regulate the antihyperalgesia, antidepressant-like effects and convulsions produced by the δ-receptor agonist SNC80. In the NTG-induced thermal hyperalgesia assay, SNC80 produced antihyperalgesia in wild-type mice, consistent with previous studies (Pradhan et al., 2014; Dripps et al., 2017) . SNC80 also decreased immobility in the FST, consistent with the wellestablished antidepressant-like effects of δ-receptor agonists (Broom et al., 2002b; Naidu et al., 2007; Saitoh et al., 2011) . RGS proteins negatively regulate G protein signalling by accelerating Gα-mediated GTP hydrolysis which returns Gα to an inactive state. This function reduces the lifetime of active Gα and diminishes downstream signalling (Traynor and Neubig, 2005) . The potency of SNC80 to produce antihyperalgesia and antidepressantlike effects was significantly increased in the Gα o RGS-insensitive heterozygous mice. These data indicate that these δ-receptormediated behaviours signal through Gα o and are negatively regulated by RGS proteins, consistent with our previous finding that RGS4 negatively regulates these behaviours (Dripps et al., 2017) . Furthermore, these enhanced effects of SNC80 were observed in mice with only one mutant copy of Gα o , demonstrating that δ-receptor-mediated signalling in vivo is highly sensitive to the effects of RGS proteins. Interestingly, the magnitude of these behavioural changes are consistent with those seen in RGS4 knockout mice, suggesting that other RGS proteins likely do not play a significant role in regulating the antihyperalgesic and antidepressant-like effects of the δ-receptor. Overall, these findings suggest that the enhanced δ-receptor-mediated antihyperalgesia and antidepressant-like effects observed in the +/GS mice are likely due to prolongation of δ-receptor-mediated G protein signalling and amplification of downstream effectors.
To confirm the role of Gα o in δ-receptor-mediated behaviours, we examined the behavioural effects of SNC80 in Gα o heterozygous knockout mice. Gα o is highly expressed in the dorsal root ganglia of the spinal cord and in the brain, comprising 0.5-1% of total brain membrane proteins (Yoo et al., 2002; for review Jiang and Bajpayee, 2009 ). SNC80-induced antihyperalgesia was abolished in Gα o heterozygous knockout mice, suggesting that Gα o is required for the antihyperalgesic effects of δ-receptor agonists. Furthermore, this profound effect was produced by only a 50% reduction in Gα o , indicating that δ-receptor-mediated antihyperalgesia is likely to require robust amplification of downstream signalling and/or is a high efficacy-requiring behaviour (i.e. has a small receptor reserve). It is possible that larger doses of SNC80 could produce antihyperalgesia in Gα o heterozygous knockout mice; however, such doses are likely to be non-selective. Taken together, our findings indicate that Gα o plays a critical role in mediating signalling required for δ-receptor-mediated antihyperalgesia.
In contrast, decreased expression of Gα o did not affect δ-receptor-mediated antidepressant-like effects in the FST. The δ-receptor could be capable of signalling through other G proteins in order to produce antidepressant-like effects and/or compensate for the reduction in Gα o expression. Alternatively, it is possible that the efficacy requirement for δ-receptor-mediated antidepressant-like effects is relatively low (i.e. has large receptor reserve) compared to that for δ-receptor-mediated antihyperalgesia in which case one functional copy of GNAO1 and approximately 50% of Gα o protein subunits (Lamberts et al., 2011) could be sufficient to produce a full response in the FST. Broom et al. (2002a) proposed that the efficacy requirement for δ-receptor-mediated antinociception was higher than that required for convulsions. The relative efficacy requirement for antidepressant-like effects has not been evaluated and will be compared with efficacy requirements for convulsions and antihyperalgesic effects in future studies.
In the present study, δ-receptor-mediated convulsions were not altered in Gα o RGSi and Gα o knockout mice. In addition, we previously observed that SNC80-induced convulsions were unaltered in RGS4 knockout mice (Dripps et al., 2017) . Overall, these data may suggest that signalling mechanisms mediating δ-receptor agonist-induced convulsions are distinct from those mediating antihyperalgesia and antidepressant-like effects. These behavioural measures could be regulated differentially by specific G protein subunits, G protein-independent signalling and/or the selective expression of signalling molecules within specific brain circuits or regions.
To address this question, we explored the hypothesis that SNC80-induced convulsions are produced by a G proteinindependent, arrestin-mediated mechanism. As first shown by Bohn et al. (1999) , we observed potentiation of morphineinduced antinociception in arrestin 3 knockout mice. Although class A GPCRs are thought to preferentially interact with arrestin 3 (Oakley et al., 2000) , no significant changes in δ-receptormediated behaviours, including convulsions, were observed in arrestin 3 knockout mice. It should be noted that these data are the result of acute administration of SNC80 and it is possible that arrestin 3 could play a role in regulating the effects of repeated doses of SNC80 or other δ-receptor agonists. This observation with SNC80 is consistent with previous reports that found that loss of arrestin 3 in mice did not alter the analgesic profile of δ-receptor agonists and had no effect on the enhanced coupling of δ-receptors to voltage-dependent calcium channels observed in the complete Freund's adjuvant (CFA) model of chronic inflammatory pain (Pradhan et al., 2013; Pradhan et al., 2016) . Overall, our findings indicate that arrestin 3 is not required for δ-receptor-mediated antihyperalgesia, antidepressant-like effects or convulsions.
In arrestin 2 knockout mice, we observed no changes in the effects of SNC80 in response to NTG-induced thermal hyperalgesia. However, it was previously demonstrated that the effects of SNC80 on CFA-induced mechanical hyperalgesia were potentiated in arrestin 2 knockout mice (Pradhan et al., 2016) . It is possible that the δ-receptor-mediated responses to these distinct pain modalities (CFA vs. NTG; mechanical vs. thermal) are differentially regulated by arrestin 2. Further studies should investigate differences in the signalling molecules and pathways mediating different types of δ-receptor-mediated antihyperalgesia. The convulsive effects of SNC80 were strongly enhanced in arrestin 2 knockout mice. The potency of SNC80 to induce convulsions was enhanced in arrestin 2 knockout mice, suggesting that arrestin 2 acts as a negative regulator of δ-receptor-mediated convulsions. Second, arrestin 2 knockout mice convulsed multiple times in response to a single dose of SNC80.
Tolerance to δ-receptor-mediated convulsions is typically acute and long lasting (Comer et al., 1993; Hong et al., 1998) . In addition, the changes in the electroencephalographic waveform produced by SNC80 return to normal baseline activity following the end of catalepsy (Jutkiewicz et al., 2006) . To our knowledge, this is the first report of multiple convulsive events in response to a δ-receptor agonist in rodents. One possible explanation for this observation is that loss of arrestin 2 produces these behavioural changes by preventing δ-receptor desensitization and/or up-regulating δ-receptor trafficking to the cell membrane resulting in enhanced δ-receptor signalling (Mittal et al., 2013) . However, in the current study, δ-receptor-mediated antidepressant-like effects and thermal antihyperalgesia were not significantly altered in arrestin 2 knockout mice. Therefore, it is possible that the behavioural effects of SNC80 are differentially regulated by arrestin 2 due to differences in regional expression, behavioural mechanisms and/or signalling downregulation and/or tolerance to the convulsive effects of SNC80. Thus, loss of arrestin 2 could allow signalling pathways that would normally be terminated to persist and produce multiple convulsive events. Future work will examine whether arrestin 2 also regulates tolerance to other behavioural effects of δ-receptor agonists.
Overall, our data demonstrate an important role for Gα o , but not arrestins, in regulating the acute antihyperalgesic and antidepressant-like effects of the δ-receptor. However, δ-receptor-mediated convulsions appear to be negatively regulated by arrestin 2 and were not altered by manipulations of Gα o function (see Figure 5 ). Taken together, these findings suggest that different signalling pathways underlie the convulsive effects of the δ-receptor, as distinct from the antihyperalgesic and antidepressant-like effects. Perhaps due in part to this phenomenon, some δ-receptor agonists do not produce convulsions at doses far exceeding those needed to produce antinociception and antidepressant-like Figure 5 Signalling molecules involved in δ-receptor-mediated behaviours. Alterations to G protein signalling pathway molecules, such as Gα o and RGS proteins, modified the antihyperalgesic and antidepressant-like effects of the δ-receptor agonist SNC80. However, arrestin 2 appears to act as a negative regulator of SNC80-induced convulsions.
Signalling bias and δ-receptor activity in vivo BJP effects (Le Bourdonnec et al., 2008; Saitoh et al., 2011; Chung et al., 2015) . However, the properties of δ-receptor agonists that determine their convulsive nature remain unclear. Ongoing work will continue to investigate the signalling mechanisms responsible for the behavioural effects of different δ-receptor agonists.
Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article.
https://doi.org/10.1111/bph.14131 Figure S1 NTG does not alter SNC80-induced convulsions. Male and female C57BL6 wild-type mice were given 10 mg·kg À1 NTG or vehicle (0.9% saline) i.p. 60 min prior to an s.c. injection of SNC80 or vehicle. Mice were then observed for 30 min for convulsive behaviours. NTG pretreatment did not significantly alter the severity of SNC80 convulsion relative to mice that received a saline pretreatment. Figure S2 The time of onset (A) and duration (B) of SNC80-induced convulsions is not significantly altered in Gαo RGSinsensitive heterozygous mice (+/GS) compared to wildtype littermates (+/+). Figure S3 The time of onset (A) and duration (B) of SNC80-induced convulsions is not significantly altered in Gαo heterozygous knockout mice (+/À) compared to wild-type littermates (+/+). Figure S4 The time of onset (A) and duration (B) of SNC80-induced convulsions is not significantly altered in arrestin 3 heterozygous (+/À) or homozygous (À/À) knockout mice compared to wild-type littermates (+/+). Figure S5 The time of onset (A) and duration (B) of SNC80-induced convulsions is not significantly altered in arrestin 2 knockout mice (À/À) compared to wild-type littermates (+/+). If a mouse exhibited multiple convulsions, only data related to the first convulsion are shown. Figure S6 Loss of arrestin 2 does not alter the potency of PTZ to induce convulsions.
